Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.

Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
Supreme Court of the United States
Argued October 15, 2014 Decided January 20, 2015
Full case name	Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
Docket no.	13-854
Citations	574 U.S. 318 (more) 135 S. Ct. 831; 190 L. Ed. 2d 719; 2014 U.S. LEXIS 4897; 83 U.S.L.W. 4055; 113 U.S.P.Q.2d 1269
Case history
Prior	810 F. Supp. 2d 578 (S.D.N.Y. 2011); 876 F. Supp. 2d 295 (S.D.N.Y. 2012); affirmed in part, reversed in part, and remanded, 723 F.3d 1363 (Fed. Cir. 2013); stay denied, 572 U.S. 1301 (2014); cert. granted, 572 U.S. 1033 (2014)
Subsequent	On remand, 789 F.3d 1335 (Fed. Cir. 2015)
Holding
When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a "clear error," not a de novo, standard of review.
Court membership
Chief Justice John Roberts Associate Justices Antonin Scalia · Anthony Kennedy Clarence Thomas · Ruth Bader Ginsburg Stephen Breyer · Samuel Alito Sonia Sotomayor · Elena Kagan
Case opinions
Majority	Breyer, joined by Roberts, Scalia, Kennedy, Ginsburg, Sotomayor, Kagan
Dissent	Thomas, joined by Alito
Laws applied
F.R.C.P. 52(a)(6)

Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 574 U.S. 318 (2015),^[1] is a landmark patent Supreme Court case disputing over the Copaxone patent.^[2][3] The Court held that, when reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a "clear error," not a de novo, standard of review.^[2][3][1]

Facts and procedural history[]

The case originated in the Southern District of New York, where Sandoz sued to invalidate Teva's patent on a drug for the treatment of multiple sclerosis. In the Markman hearing, Sandoz argued that a claim was fatally for failing to identify which of three possible meanings a particular claim term, related to the molecular weight of a component of the drug, should be interpreted to have. The district court judge held that the claim term was definite, and that a "person of ordinary skill in the art" would interpret the term "molecular weight" to mean the "peak average molecular weight", that is, the weight of the molecule most prevalent in the mixture.^[4] In doing so, the judge relied in part on expert witness testimony.

Sandoz appealed to the Federal Circuit, which reviewed the claim under a 'de novo' standard, decided that the claim term was fatally indefinite, and hence that the patent was invalid.^[5]

Teva appealed to the US Supreme Court and won.

References[]

External links[]

• Text of Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 574 U.S. 318 (2015) is available from: CourtListener  Google Scholar  Justia  Oyez (oral argument audio)  Supreme Court (slip opinion)